Administration ends temporary Medicare drug-plan subsidy, setting up higher Part D costs in 2027

The Trump administration is ending a temporary federal subsidy for Medicare Part D prescription-drug plans, a decision expected to make coverage more expensive for many older adults beginning in 2027.

The subsidy helped offset Part D premiums for two years. It reduced the average premium by about $16 in 2026, according to the Medicare Payment Advisory Commission, or MedPAC. The program was estimated to cost the federal government $3.6 billion in 2026.

The policy applies nationally to Medicare prescription-drug plans. Its end does not mean that every Medicare beneficiary will pay more, and the size of any increase has not yet been determined. Costs will vary by plan.

What is changing

The administration’s decision removes the temporary support that had helped hold down Part D premiums. The change shifts more of the insurance cost away from the federal government and plans and toward Medicare beneficiaries, including older adults who may be managing prescription costs on fixed incomes.

The administration says ending the subsidy will prevent federal money from being directed to insurance companies. Critics counter that the decision could make Part D coverage less affordable, particularly as negotiated Medicare drug-price savings begin.

Those competing explanations describe the policy differently. The administration is emphasizing federal spending and the flow of subsidy payments. Critics are emphasizing what beneficiaries may face when the premium offset is no longer available. The approved information does not establish which individual plans will raise premiums or by how much.

Why the 2027 timing matters

The immediate effect is not a confirmed increase in 2027 premiums. Instead, the decision sets up the possibility of higher monthly costs when the temporary subsidy ends. Millions of older adults could be affected, but the final impact will depend on the Medicare drug plan each person has and the premiums those plans set.

For beneficiaries, the practical question will be how the end of the subsidy changes the cost of maintaining prescription-drug coverage. A monthly increase that is smaller for one plan could be larger for another. The current information does not provide a final premium schedule or an individual estimate.

The roughly $16 average monthly offset in 2026 provides a measure of the support that is ending, but it is not a forecast of every beneficiary’s 2027 bill. It is also not evidence that all Part D enrollees will see the same change.

What happens next

Higher beneficiary costs are expected to begin in 2027, after the two-year subsidy period ends. The next key information will be the premiums and plan-specific costs that become available for that coverage year.

Until those figures are released, the overall direction of the policy is known while the effect on individual households is not. Medicare beneficiaries will need to compare the costs of their available Part D options once the 2027 plan information is available. The administration’s decision ends the temporary federal premium support; it does not eliminate Medicare drug-price negotiation.

For older adults on fixed incomes, the change could make the annual choice of prescription-drug coverage more consequential. Whether a particular beneficiary pays more, and how much, will depend on the plan rather than on the national average alone.